瑞典推出多重耐药结核杆菌的快速检测

 
 
结核(TB)药物耐药是一个严重的公共健康问题。一种新型多药耐药结核(MDR-TB)诊断检测只需要2天就能够提供检测结果。

这种新型检测比传统的检测方法更快的提供结果，传统方法需要数周才能够给出检测结果。MDR-TB的分子学检测十分迅速，但是技术更复杂而且价格昂贵。FastPlaque-Response是由创新新型检测FIND(Geneva, Switzerland)基金研制开发的，这是由Bill和Melinda Gates与Biotec Laboratories(Ipswich, UK)创建的。该检测已经在欧洲注册正在接受FIND的评估，以用于TB高流行的国家。

Rapid Test Detects Multi-Drug-Resistant TB
 
Tuberculosis (TB) drug resistance is a major public health problem. A new diagnostic test for multi-drug-resistant TB (MDR-TB) provides results in only two days.

The new test is much faster than conventional methods that take weeks to yield results. Molecular tests for MDR-TB are also rapid but are much more technically complicated and expensive. The FastPlaque-Response was developed by the Foundation for Innovative New Diagnostics FIND (Geneva, Switzerland), which is a Bill and Melinda Gates initiative, and Biotec Laboratories Ltd. (Ipswich, UK). The test has been registered in Europe and is in the process of being evaluated by FIND for use within the public health sector of countries where there is a high incidence of TB.